1. Inhibitor of MAP kinase activation blocks colon cancer growth
Dan Gordon 
Gastroenterology 
Volume 117, Issue 3, (September 1999)
DOI: /S (99)
Copyright © Terms and Conditions

2. Fig. 1
PD , a potent, highly specific, and orally active inhibitor of MEK (MAP kinase kinase) acts at a critical convergence point through which receptor tyrosine kinases (RTK) and G protein-coupled receptors (GPCR) activate MAP kinase and stimulate multiple downstream effects including tumor cell proliferation.
Gastroenterology  , DOI: ( /S (99) )
Copyright © Terms and Conditions